Clinical Trials Browser

NIH × cemiplimab × Endocrine × Clear all

NCT06900595 2026-03-18

Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer

Phase 2 Recruiting

Adrenocortical Carcinoma